-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345

Benzinga·08/07/2026 19:36:55
Listen to the news
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $340 to $345.